3 Key Considerations for Implementing Biosimilars in Health Systems


Rick Lozano, vice president of biosimilars and integrated business development for AmerisourceBergen, shares the three considerations for implementing biosimilars in the health system setting.
It’s no secret that hospitals and health systems continue to face pressure to improve patient outcomes while managing the total cost of care. Now, biosimilars present an opportunity to address both needs. They are clinically equivalent to reference biologic products and offer potentially significant savings. Yet many hospitals struggle to change their formularies and physician preferences for these medications. 

Still, health systems are a critical channel not only to ensure biosimilars’ success, but also to ensure that patients, providers, and the collective healthcare system are receiving the full benefit of this new class of therapies. Manufacturers will need to work with hospital teams to develop a process to evaluate and support biosimilars as an addition to or replacement for reference products. That starts by understanding 3 key considerations for assisting health systems implementing biosimilars: safety and efficacy, operational support and economic impact, and workflow and access.

To read the full article, as originally published in The Center for Biosimilars, click here.